Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases using Alpharadin, compared to the interim analysis from June 2011. • Overall survival in Alpharadin arm increased by 44% • [...]
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]
In a study presented at ASCO, researchers found that the drug duloxetine (Cymbalta) can help to treat peripheral neuropathy, a painful side effect of chemotherapy using taxanes. Taxotere, the chemotherapy drug used to treat castrate resistant, advanced prostate cancer is a taxane. Peripheral neuropathy occurs when nerves in the body's peripheral nervous system (outside the [...]
At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]